论文部分内容阅读
目的:探讨趋化因子受体9(chemokine receptor 9,CCR9)在非小细胞肺癌(non-small cell lung cancer,NSCLC)发生、发展中的作用及其与Survivin、Bcl-2蛋白表达的相关性。方法:免疫组织化学法检测80例NSCLC组织及其癌旁正常肺组织中CCR9、Survivin和Bcl-2的表达。结果:NSCLC组织中CCR9阳性表达率为61.25%(49/80),明显高于正常对照组的3.75%(3/80),χ2=60.285,P<0.001;CCR9在腺癌组织的阳性率为73.53%(25/34),高于鳞癌的50.00%(20/40),χ2=4.270,P=0.039。CCR9在有淋巴结转移者的阳性表达率为90.48%(38/42),高于无淋巴结转移者的28.95%(11/38),χ2=31.822,P<0.001;CCR9在临床Ⅲ+Ⅳ期的阳性表达率为81.82%(27/33),高于Ⅰ+Ⅱ期的46.81%(22/47),χ2=10.012,P=0.002。CCR9表达与患者性别、年龄、分化程度及T状态方面无明显相关性,P>0.05。NSCLC组织中CCR9表达与Survivin、Bcl-2表达正相关,P值分别为<0.001和0.007,Pearson’s R分别为0.708和0.302。结论:CCR9可能通过抑制细胞凋亡,在NSCLC的发生、发展中可能起着重要作用,其阳性表达可能预示着肿瘤的高侵袭性和不良预后。CCR9与Survivin、Bcl-2的共同表达可能在NSCLC中起着协同作用。
Objective: To investigate the role of chemokine receptor 9 (CCR9) in the development and progression of non-small cell lung cancer (NSCLC) and its relationship with the expression of Survivin and Bcl-2 . Methods: The expressions of CCR9, Survivin and Bcl-2 in 80 NSCLC tissues and adjacent normal lung tissues were detected by immunohistochemistry. Results: The positive rate of CCR9 in NSCLC was 61.25% (49/80), significantly higher than that in normal control (3.75%, 3/2), χ2 = 60.285, P <0.001. The positive rate of CCR9 in adenocarcinoma was 73.53% (25/34), higher than squamous cell carcinoma 50.00% (20/40), χ2 = 4.270, P = 0.039. The positive rate of CCR9 in patients with lymph node metastasis was 90.48% (38/42), which was higher than that in patients without lymph node metastasis (28.95%, 11/38) (χ2 = 31.822, P <0.001) The positive rate was 81.82% (27/33), which was higher than 46.81% (22/47) in stage Ⅰ + Ⅱ, χ2 = 10.012, P = 0.002. There was no significant correlation between CCR9 expression and gender, age, differentiation and T status of patients (P> 0.05). The expression of CCR9 in NSCLC tissues was positively correlated with the expression of Survivin and Bcl-2, the P values were <0.001 and 0.007 respectively, and Pearson’s R were 0.708 and 0.302 respectively. Conclusion: CCR9 may play an important role in the occurrence and development of NSCLC possibly by inhibiting apoptosis. The positive expression of CCR9 may predict the high aggressiveness and poor prognosis of NSCLC. Co-expression of CCR9 with Survivin and Bcl-2 may play a synergistic role in NSCLC.